Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia.

Humans Waldenstrom Macroglobulinemia / diagnosis Myeloid Differentiation Factor 88 / genetics In Situ Hybridization, Fluorescence Mutation
CXCR4 IgM MGUS MYD88 TERT TP53 Waldenström's Macroglobulinemia

Journal

Seminars in hematology
ISSN: 1532-8686
Titre abrégé: Semin Hematol
Pays: United States
ID NLM: 0404514

Informations de publication

Date de publication:
Mar 2023
Historique:
received: 23 03 2023
accepted: 23 03 2023
medline: 19 6 2023
pubmed: 26 4 2023
entrez: 26 4 2023
Statut: ppublish

Résumé

Apart from the MYD88

Identifiants

DOI: 10.1053/j.seminhematol.2023.03.007 PMID: 37099028
pubmed: 37099028
pii: S0037-1963(23)00027-6
doi: 10.1053/j.seminhematol.2023.03.007
pii:
doi:

Substances chimiques

Myeloid Differentiation Factor 88 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

90-96

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Auteurs

Ramón Garcia-Sanz (R)

Hematology Department, University Hospital of Salamanca, Research Biomedical Institute of Salamanca (IBSAL), CIBERONC and Center for Cancer Research-IBMCC (University of Salamanca-CSIC), Salamanca, Spain. Electronic address: rgacias@usal.es.

Marzia Varettoni (M)

Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Italy.

Cristina Jiménez (C)

Hematology Department, University Hospital of Salamanca, Research Biomedical Institute of Salamanca (IBSAL), CIBERONC and Center for Cancer Research-IBMCC (University of Salamanca-CSIC), Salamanca, Spain.

Simone Ferrero (S)

Unit of Hematology, Department of Biotechnology & Health Sciences, University of Torino, Torino, Italy.

Stephanie Poulain (S)

Laboratory of Hematology, Biology and Pathology Center, CHU of Lille, UMR9020 CNRS-U1277 INSERM, University of Lille, and ONCOLILLE Cancer Institute, CANTHER Laboratory, Lille, France.

Jesus F San-Miguel (JF)

Laboratory of Hematology, Biology and Pathology Center, CHU of Lille, Lille, France.

Maria L Guerrera (ML)

Hematology department, Clínica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain.

Daniela Drandi (D)

Unit of Hematology, Department of Biotechnology & Health Sciences, University of Torino, Torino, Italy.

Tina Bagratuni (T)

Bing Center for Waldenström's Macroglobulinemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

Mary McMaster (M)

Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Aldo M Roccaro (AM)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.

Damien Roos-Weil (D)

Clinical Trial Center, Translational Research and Phase I Unit, ASST Spedali Civili di Brescia, Brescia, Italy.

Merav Leiba (M)

Sorbonne Université, Hematology Unit, Pitié-Salpêtrière Hospital, Assitance Publique des Hôpitaux de Paris (AP-HP), Paris, France.

Yong Li (Y)

Assuta Ashdod University Hospital, Faculty of Health Science, Ben-Gurion University of the Negev, Negev, Israel.

Luigi Qiu (L)

Department of Medicine, Baylor College of Medicine, Houston, TX.

Jian Hou (J)

National Clinical Research Center for Blood Diseases, Blood Disease Hospital and Institute of Hematology), Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.

C Fernandez De Larrea (CF)

Renji Hospital, Shanghai, China.

Jorge J Castillo (JJ)

Hematology department, Clínica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain.

M Dimopoulos (M)

Bing Center for Waldenström's Macroglobulinemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

R G Owen (RG)

Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, Barcelona, Spain; St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

S P Treon (SP)

Hematology department, Clínica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain.

Z R Hunter (ZR)

Hematology department, Clínica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Report of Consensus Panel 3 from the 11th...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Paraprotéinémies › Macroglobulinémie de Waldenström › Report of Consensus Panel 3 from the 11th...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protéines adaptatrices de la transduction du signal › Facteur de différenciation myéloïde-88 › Report of Consensus Panel 3 from the 11th...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Hybridation in situ › Hybridation fluorescente in situ › Report of Consensus Panel 3 from the 11th...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Report of Consensus Panel 3 from the 11th...